Advances in targeting the extracellular matrix for glaucoma therapy: current updates

References

• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmol. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013
   PubMed Web of Science ®Google Scholar
• Musch DC, Gillespie BW, Lichter PR, et al. Visual field progression in the collaborative initial glaucoma treatment study the impact of treatment and other baseline factors. Ophthalmol. 2009;116(2):200–207. doi: 10.1016/j.ophtha.2008.08.051
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Flow of aqueous humor in humans [the friedenwald lecture]. Invest Ophthalmol Vis Sci. 1991;32(13):3145–3166. https://iovs.arvojournals.org/article.aspx?articleid=2160397
   PubMed Web of Science ®Google Scholar
• Toris CB, Koepsell SA, Yablonski ME, et al. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002;11(3):253–258. doi: 10.1097/00061198-200206000-00015
   PubMed Web of Science ®Google Scholar
• Johnson M. What controls aqueous humour outflow resistance?. Exp Eye Res. 2006;82(4):545–557. doi: 10.1016/j.exer.2005.10.011
   PubMed Web of Science ®Google Scholar
• Acott TS, Vranka JA, Keller KE, et al. Normal and glaucomatous outflow regulation. Prog Retin Eye Res. 2021;82:100897. doi: 10.1016/j.preteyeres.2020.100897
   PubMed Web of Science ®Google Scholar
• Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39(13):2649–2658. https://iovs.arvojournals.org/article.aspx?articleid=2161843
   PubMed Web of Science ®Google Scholar
• Gottanka J, Johnson DH, Martus P, et al. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J Glaucoma. 1997;6(2):123–132. doi: 10.1097/00061198-199704000-00009
   PubMed Web of Science ®Google Scholar
• Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res. 2008;86(4):543–561. doi: 10.1016/j.exer.2008.01.013
   PubMed Web of Science ®Google Scholar
• Ueda J, Wentz-Hunter K, Yue BY. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci. 2002;43(4):1068–1076. https://iovs.arvojournals.org/article.aspx?articleid=2200196
   PubMed Web of Science ®Google Scholar
• Kasetti RB, Maddineni P, Millar JC, et al. Increased synthesis and deposition of extracellular matrix proteins leads to endoplasmic reticulum stress in the trabecular meshwork. Sci Rep. 2017;7(1):14951. doi: 10.1038/s41598-017-14938-0
   PubMed Web of Science ®Google Scholar
• Agarwal R, Agarwal P. Future target molecules in antiglaucoma therapy: TGF-Beta may have a role to play. Ophthalmic Res. 2010;43(1):1–10. doi: 10.1159/000246571
   PubMed Web of Science ®Google Scholar
• Agarwal P, Daher AM, Agarwal R. Aqueous humor TGF-β2 levels in patients with open-angle glaucoma: a meta-analysis. Mol Vis. 2015;21:612–620. http://www.molvis.org/molvis/v21/612/
   PubMed Web of Science ®Google Scholar
• Zhao X, Ramsey KE, Stephan DA, et al. Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest Ophthalmol Vis Sci. 2004;45(11):4023–4034. doi: 10.1167/iovs.04-0535
   PubMed Web of Science ®Google Scholar
• Fleenor DL, Shepard AR, Hellberg PE, et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47(1):226–234. doi: 10.1167/iovs.05-1060
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Hirano S, Suzuki K, et al. Signaling mechanism of TGF-beta1-induced collagen contraction mediated by bovine trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2002;43(11):3465–3472. https://iovs.arvojournals.org/article.aspx?articleid=2123155
   PubMed Web of Science ®Google Scholar
• Hill LJ, Mead B, Thomas CN, et al. TGF-β-induced IOP elevations are mediated by RhoA in the early but not the late fibrotic phase of open angle glaucoma. Mol Vis. 2018;24:712–726. http://www.molvis.org/molvis/v24/712/
   PubMed Web of Science ®Google Scholar
• Sethi A, Mao W, Wordinger RJ, et al. Transforming growth factor-beta induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(8):5240–5250. doi: 10.1167/iovs.11-7287
   PubMed Web of Science ®Google Scholar
• Welge-Lüssen U, May CA, Lütjen-Drecoll E. Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2. Invest Ophthalmol Vis Sci. 2000;41(8):2229–2238. https://iovs.arvojournals.org/article.aspx?articleid=2123029
   PubMed Web of Science ®Google Scholar
• Raychaudhuri U, Millar JC, Clark AF. Tissue Transglutaminase Elevates Intraocular Pressure in Mice. Invest Ophthalmol Vis Sci. 2017;58(14):6197–6211. doi: 10.1167/iovs.17-22236
   PubMed Web of Science ®Google Scholar
• Cousins SW, McCabe MM, Danielpour D, et al. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2201–2211. https://iovs.arvojournals.org/article.aspx?articleid=2160493
   PubMed Web of Science ®Google Scholar
• Pervan CL, Lautz JD, Blitzer AL, et al. Rho GTPase signaling promotes constitutive expression and release of TGF-β2 by human trabecular meshwork cells. Exp Eye Res. 2016;146:95–102. doi: 10.1016/j.exer.2015.12.010
   PubMed Web of Science ®Google Scholar
• Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1–2):59–69. doi: 10.1016/s1359-6101(99)00029-5
   PubMed Web of Science ®Google Scholar
• Kang MH, Oh DJ, Kang JH, et al. Regulation of SPARC by transforming growth factor β2 in human trabecular meshwork. Invest Ophthalmol Vis Sci. 2013;54(4):2523–2532. doi: 10.1167/iovs.12-11474
   PubMed Web of Science ®Google Scholar
• Haddadin RI, Oh DJ, Kang MH, et al. SPARC-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 2009;50(8):3771–3777. doi: 10.1167/iovs.08-2489
   PubMed Web of Science ®Google Scholar
• Wilson SE. TGF beta -1, -2 and -3 in the modulation of fibrosis in the cornea and other organs. Exp Eye Res. 2021;207:108594. doi: 10.1016/j.exer.2021.108594
   PubMed Web of Science ®Google Scholar
• Junglas B, Yu AH, Welge-Lüssen U, et al. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp Eye Res. 2009;88(6):1065–1075. doi: 10.1016/j.exer.2009.01.008
   PubMed Web of Science ®Google Scholar
• Tovar-Vidales T, Clark AF, Wordinger RJ. Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. Exp Eye Res. 2011;93(4):442–451. doi: 10.1016/j.exer.2011.06.011
   PubMed Web of Science ®Google Scholar
• Finnson KW, Almadani Y, Philip A. Non-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: mechanisms and targets. Semin Cell Dev Biol. 2020;101:115–122. doi: 10.1016/j.semcdb.2019.11.013
   PubMed Web of Science ®Google Scholar
• Pervan CL. Smad-independent TGF-β2 signaling pathways in human trabecular meshwork cells. Exp Eye Res. 2017;158:137–145. doi: 10.1016/j.exer.2016.07.012
   PubMed Web of Science ®Google Scholar
• Hassan MDS, Razali N, Abu Bakar AS, et al. Connective tissue growth factor: role in trabecular meshwork remodeling and intraocular pressure lowering. Exp Biol Med (Maywood). 2023;248(16):1425–1436. doi: 10.1177/15353702231199466
   PubMedGoogle Scholar
• Mori S, Matsuzaki K, Yoshida K, et al. TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions. Oncogene. 2004;23(44):7416–7429. doi: 10.1038/sj.onc.1207981
   PubMed Web of Science ®Google Scholar
• Han H, Wecker T, Grehn F, et al. Elasticity-dependent modulation of TGF-β responses in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(6):2889–2896. doi: 10.1167/iovs.10-6640
   PubMed Web of Science ®Google Scholar
• Peng F, Zhang B, Wu D, et al. Tgfbeta-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol. 2008;295(1):F153–F164. doi: 10.1152/ajprenal.00419.2007
   PubMed Web of Science ®Google Scholar
• Wang J, Liu X, Zhong Y. Rho/rho-associated kinase pathway in glaucoma. Int J Oncol. 2013;43(5):1357–1367. doi: 10.3892/ijo.2013.2100
   PubMed Web of Science ®Google Scholar
• Shyam R, Shen X, Yue BY, et al. Wnt gene expression in human trabecular meshwork cells. Mol Vis. 2010;16:122–9.
   PubMed Web of Science ®Google Scholar
• Miller JR, Hocking AM, Brown JD, et al. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 1999;18(55):7860–7872. doi: 10.1038/sj.onc.1203245
   PubMed Web of Science ®Google Scholar
• Villarreal G Jr, Chatterjee A, Oh SS, et al. Canonical Wnt signaling regulates extracellular matrix expression in the trabecular meshwork. Invest Ophthalmol Vis Sci query. 2014;55(11):7433–7440. doi: 10.1167/iovs.13-12652
   PubMed Web of Science ®Google Scholar
• Dhamodaran K, Baidouri H, Sandoval L, et al. Wnt activation after inhibition restores trabecular meshwork cells toward a normal phenotype. Invest Ophthalmol Vis Sci. 2020;61(6):30. doi: 10.1167/iovs.61.6.30
   PubMed Web of Science ®Google Scholar
• Wang WH, McNatt LG, Pang IH, et al. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J Clin Invest. 2008;118(3):1056–1064. doi: 10.1172/JCI33871
   PubMed Web of Science ®Google Scholar
• Sugali CK, Rayana NP, Dai J, et al. The canonical wnt signaling pathway inhibits the glucocorticoid receptor signaling pathway in the trabecular meshwork. Am J Pathol. 2021;191(6):1020–1035. doi: 10.1016/j.ajpath.2021.02.018
   PubMed Web of Science ®Google Scholar
• Webber HC, Bermudez JY, Sethi A, et al. Crosstalk between TGFβ and Wnt signaling pathways in the human trabecular meshwork. Exp Eye Res. 2016;148:97–102. doi: 10.1016/j.exer.2016.04.007
   PubMed Web of Science ®Google Scholar
• Wecker T, Han H, Börner J, et al. Effects of TGF-β2 on cadherins and β-catenin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2013;54(10):6456–6462. doi: 10.1167/iovs.13-12669
   PubMed Web of Science ®Google Scholar
• Gagen D, Faralli JA, Filla MS, et al. The role of integrins in the trabecular meshwork. J Ocul Pharmacol Ther. 2014;30(2–3):110–120. doi: 10.1089/jop.2013.0176
   PubMed Web of Science ®Google Scholar
• Shi F, Harman J, Fujiwara K, et al. Collagen I matrix turnover is regulated by fibronectin polymerization. Am J Physiol Cell Physiol. 2010;298(5):C1265–C1275. doi: 10.1152/ajpcell.00341.2009
   PubMed Web of Science ®Google Scholar
• Wu C, Hughes PE, Ginsberg MH, et al. Identification of a new biological function for the integrin alpha v beta 3: initiation of fibronectin matrix assembly. Cell Adhes Commun. 1996;4(3):149–158. doi: 10.3109/15419069609014219
   PubMed Web of Science ®Google Scholar
• Wang D, Sun L, Zborowska E, et al. Control of type II transforming growth factor-beta receptor expression by integrin ligation. J Biol Chem. 1999;274(18):12840–12847. doi: 10.1074/jbc.274.18.12840
   PubMed Web of Science ®Google Scholar
• Shan SW, Do CW, Lam TC, et al. Thrombospondin-1 mediates Rho-kinase inhibitor-induced increase in outflow-facility. J Cell Physiol. 2021;236(12):8226–8238. doi: 10.1002/jcp.30492
   PubMed Web of Science ®Google Scholar
• Alam N, Goel HL, Zarif MJ, et al. The integrin-growth factor receptor duet. J Cell Physiol. 2007;213(3):649–653. doi: 10.1002/jcp.21278
   PubMed Web of Science ®Google Scholar
• Munger JS, Sheppard D. Cross talk among TGF-β signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol. 2011;3(11):a005017. doi: 10.1101/cshperspect.a005017
   PubMed Web of Science ®Google Scholar
• Taurone S, Ripandelli G, Pacella E, et al. Potential regulatory molecules in the human trabecular meshwork of patients with glaucoma: immunohistochemical profile of a number of inflammatory cytokines. Mol Med Rep. 2015;11(2):1384–1390. doi: 10.3892/mmr.2014.2772
   PubMed Web of Science ®Google Scholar
• Liton PB, Li G, Luna C, et al. Cross-talk between TGF-beta1 and IL-6 in human trabecular meshwork cells. Mol Vis. 2009;15:326–334.
   PubMed Web of Science ®Google Scholar
• Inoue-Mochita M, Inoue T, Kojima S, et al. Interleukin-6-mediated trans-signaling inhibits transforming growth factor-β signaling in trabecular meshwork cells. J Biol Chem. 2018;293(28):10975–10984. doi: 10.1074/jbc.RA118.003298
   PubMed Web of Science ®Google Scholar
• Liu ZW, Zhang YM, Zhang LY, et al. Duality of interactions between TGF-β and TNF-α during tumor formation. Front Immunol. 2022;12:810286. doi: 10.3389/fimmu.2021.810286
   PubMed Web of Science ®Google Scholar
• Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17(3):276–285. doi: 10.1076/ceyr.17.3.276.5219
   PubMed Web of Science ®Google Scholar
• Holappa M, Vapaatalo H, Vaajanen A. Many faces of Renin-angiotensin system - focus on Eye. Open Ophthalmol J. 2017;11(1):122–142. doi: 10.2174/1874364101711010122
   PubMedGoogle Scholar
• Agarwal P, Agarwal R. Trabecular meshwork ECM remodeling in glaucoma: could RAS be a target? Expert Opin Ther targets. Expert Opin Ther Targets. 2018;22(7):629–638. doi: 10.1080/14728222.2018.1486822
   PubMed Web of Science ®Google Scholar
• Inoue T, Yokoyoma T, Koike H. The effect of angiotensin II on uveoscleral outflow in rabbits. Curr Eye Res. 2001;23(2):139–143. doi: 10.1076/ceyr.23.2.139.5470
   PubMed Web of Science ®Google Scholar
• Vaajanen A, Vapaatalo H, Kautiainen H, et al. Angiotensin (1-7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci. 2008;49(6):2557–2562. doi: 10.1167/iovs.07-1399
   PubMed Web of Science ®Google Scholar
• Li H, Cui H, Ren J, et al. Elevated angiotensin-II levels contribute to the pathogenesis of open-angle glaucoma via inducing the expression of fibrosis-related genes in trabecular meshwork cells through a ROS/NOX4/SMAD3 axis. Cell Transplant. 2023;32:9636897231162526. doi: 10.1177/09636897231162526
   Web of Science ®Google Scholar
• Rupérez M, Lorenzo O, Blanco-Colio LM, et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003;108(12):1499–1505. doi: 10.1161/01.CIR.0000089129.51288.BA
   PubMed Web of Science ®Google Scholar
• Choritz L, Machert M, Thieme H. Correlation of endothelin-1 concentration in aqueous humor with intraocular pressure in primary open angle and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2012;53(11):7336–7342. doi: 10.1167/iovs.12-10216
   PubMed Web of Science ®Google Scholar
• Wang J, Rong Y, Liu Y, et al. The effect of ET1-CTGF mediated pathway on the accumulation of extracellular matrix in the trabecular meshwork and its contribution to the increase in IOP. Int Ophthalmol. 2023;43(9):3297–3307. doi: 10.1007/s10792-023-02733-y
   PubMed Web of Science ®Google Scholar
• Song B, Zhang ZZ, Zhong JC, et al. Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway. Circ J. 2013;77(12):2997–3006. doi: 10.1253/circj.CJ-13-0805
   PubMed Web of Science ®Google Scholar
• Kagami S, Border WA, Miller DE, et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93(6):2431–2437. doi: 10.1172/JCI117251
   PubMed Web of Science ®Google Scholar
• Weigert C, Brodbeck K, Klopfer K, et al. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia. 2002;5(6):890–898. doi: 10.1007/s00125-002-0843-4
   Google Scholar
• Zhou Y, Poctatek MH, Berecek KH, et al. Thrombospondin 1 mediates angiotensin II induction of TGF-β activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun. 2006;339(2):633–641. doi: 10.1016/j.bbrc.2005.11.060
   PubMed Web of Science ®Google Scholar
• Wolf G, Ziyadeh FN, Stahl R. Angiotensin II stimulates expression of transforming growth factor β receptor type II in cultured mouse proximal tubular cells. J Mol Med. 1999;77(7):556–564. doi: 10.1007/s001099900028
   PubMed Web of Science ®Google Scholar
• De Groef L, Andries L, Siwakoti A, et al. Aberrant collagen composition of the trabecular meshwork results in reduced aqueous humor drainage and elevated IOP in MMP-9 null mice. Invest Ophthalmol Vis Sci. 2016;57(14):5984–5995. doi: 10.1167/iovs.16-19734
   PubMed Web of Science ®Google Scholar
• Määttä M, Tervahartiala T, Harju M, et al. Matrix metalloproteinases and their tissue inhibitors in aqueous humor of patients with primary open-angle glaucoma, exfoliation syndrome, and exfoliation glaucoma. J Glaucoma. 2005;14(1):64–69. doi: 10.1097/01.ijg.0000145812.39224.0a
   PubMed Web of Science ®Google Scholar
• Razali N, Agarwal R, Agarwal P, et al. Anterior and posterior segment changes in rat eyes with chronic steroid administration and their responsiveness to antiglaucoma drugs. Eur J Pharmacol. 2015;749:73–80. doi: 10.1016/j.ejphar.2014.11.029
   PubMed Web of Science ®Google Scholar
• Razali N, Agarwal R, Agarwal P, et al. Topical trans-resveratrol ameliorates steroid-induced anterior and posterior segment changes in rats. Exp Eye Res. 2016;143:9–16. doi: 10.1016/j.exer.2015.09.014
   PubMed Web of Science ®Google Scholar
• Gindina S, Hu Y, Barron AO, et al. Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma. Exp Eye Res. 2020;199:108179. doi: 10.1016/j.exer.2020.108179
   PubMed Web of Science ®Google Scholar
• Zhao Y, Lyons CE Jr, Xiao A, et al. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochemical And Biophysical Research Communications. 2008;369(4):1215–1220. doi: 10.1016/j.bbrc.2008.03.038
   PubMed Web of Science ®Google Scholar
• Kohler HP, Grant PJ, Epstein FH. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342(24):1792–1801. doi: 10.1056/NEJM200006153422406
   PubMed Web of Science ®Google Scholar
• Dan J, Belyea D, Gertner G, et al. Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma. Arch Ophthalmol. 2005;123(2):220–224. doi: 10.1001/archopht.123.2.220
   PubMedGoogle Scholar
• Zhong S, Khalil RA. A disintegrin and metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochem Pharmacol. 2019;164:188–204. doi: 10.1016/j.bcp.2019.03.033
   PubMed Web of Science ®Google Scholar
• Keller KE, Bradley JM, Acott TS. Differential effects of ADAMTS-1, -4, and -5 in the trabecular meshwork. Invest Ophthalmol Vis Sci. 2009;50(12):5769–5777. doi: 10.1167/iovs.09-3673
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Agarwal R, Talati M, et al. Expression of bone morphogenetic proteins (BMP), BMP receptors, and BMP associated proteins in human trabecular meshwork and optic nerve head cells and tissues. Mol Vis. 2002;8:241–250. http://www.molvis.org/molvis/v8/a31/
   PubMed Web of Science ®Google Scholar
• Fuchshofer R, Stephan DA, Russell P, et al. Gene expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork cells: identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp Eye Res. 2009;88(6):1020–1032. doi: 10.1016/j.exer.2009.01.002
   PubMed Web of Science ®Google Scholar
• Wordinger RJ, Sharma T, Clark AF. The role of TGF-β2 and bone morphogenetic proteins in the trabecular meshwork and glaucoma. J Ocul Pharmacol Ther. 2014;30(2–3):154–162. doi: 10.1089/jop.2013.0220
   PubMed Web of Science ®Google Scholar
• Shimasaki S, Moore RK, Otsuka F, et al. The bone morphogenetic protein system in mammalian reproduction. Endocr Rev. 2004;25(1):72–101. doi: 10.1210/er.2003-0007
   PubMed Web of Science ®Google Scholar
• Sethi A, Wordinger RJ, Clark AF. Gremlin utilizes canonical and non-canonical TGFβ signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells. Exp Eye Res. 2013;113:117–127. doi: 10.1016/j.exer.2013.05.011
   PubMed Web of Science ®Google Scholar
• Hernandez H, Millar JC, Curry SM, et al. BMP and activin membrane bound inhibitor regulates the extracellular matrix in the trabecular meshwork. Invest Ophthalmol Vis Sci. 2018;59(5):2154–2166. doi: 10.1167/iovs.17-23282
   PubMed Web of Science ®Google Scholar
• Yan X, Lin Z, Chen F, et al. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem. 2009;284(44):30097–30104. doi: 10.1074/jbc.M109.049304
   PubMed Web of Science ®Google Scholar
• Mzyk P, Hernandez H, Le T, et al. Toll-like receptor 4 signaling in the trabecular meshwork. Front Cell Dev Biol. 2022;10:936115. doi: 10.3389/fcell.2022.936115
   PubMed Web of Science ®Google Scholar
• McKeown-Longo PJ, Higgins PJ. Integration of canonical and noncanonical pathways in TLR4 signaling: complex regulation of the wound repair program. Adv Wound Care (New Rochelle). 2017;6(10):320–329. doi: 10.1089/wound.2017.0736
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375–13378. doi: 10.1074/jbc.273.22.13375
   PubMed Web of Science ®Google Scholar
• Trojanowska M. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol. 2009;21(6):623–629. doi: 10.1097/BOR.0b013e32833038ce
   PubMed Web of Science ®Google Scholar
• Tellios N, Belrose JC, Tokarewicz AC, et al. TGF-β induces phosphorylation of phosphatase and tensin homolog: implications for fibrosis of the trabecular meshwork tissue in glaucoma. Sci Rep. 2017;7(1):812. doi: 10.1038/s41598-017-00845-x
   PubMedGoogle Scholar
• Igarashi N, Honjo M, Aihara M. mTOR inhibitors potentially reduce TGF-β2-induced fibrogenic changes in trabecular meshwork cells. Sci Rep. 2021;11(1):14111. doi: 10.1038/s41598-021-93580-3
   PubMed Web of Science ®Google Scholar
• Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci. 2003;44(8):3394–33401. doi: 10.1167/iovs.02-0978
   PubMed Web of Science ®Google Scholar
• CAT-152 0102 Trabeculectomy Study Group, Khaw P, Grehn F, et al. A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmol. 2007;114(10):1822–1830. doi: 10.1016/j.ophtha.2007.03.050
   PubMed Web of Science ®Google Scholar
• Teplitsky JE, Vinokurtseva A, Armstrong JJ, et al. ALK5 inhibition of subconjunctival scarring from glaucoma surgery: effects of SB-431542 compared to mitomycin C in human tenon’s capsule fibroblasts. Transl Vis Sci Technol. 2023;12(2):31. doi: 10.1167/tvst.12.2.31
   PubMedGoogle Scholar
• Pfeiffer N, Voykov B, Renieri G, et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery. PLoS One. 2017;12(11):e0188899. doi: 10.1371/journal.pone.0188899
   PubMed Web of Science ®Google Scholar
• Oshitari T, Wang N, Li AF, et al. Excess fibronectin accumulation in the trabecular meshwork: a potential mechanism for increasing aqueous outflow resistance. Invest Ophthalmol Vis Sci. 2006;47(13):1837–1837. https://iovs.arvojournals.org/article.aspx?articleid=2391694
   Google Scholar
• Luna C, Li G, Qiu J, et al. Cross-talk between miR-29 and transforming growth factor-betas in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(6):3567–3572. doi: 10.1167/iovs.10-6448
   PubMed Web of Science ®Google Scholar
• Stahnke T, Kowtharapu BS, Stachs O, et al. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PLoS One. 2017;12(2):e0172592. doi: 10.1371/journal.pone.0172592
   PubMed Web of Science ®Google Scholar
• Knox J, Bou-Gharios G, Hamill KJ, et al. MiR-18a-5p targets connective tissue growth factor expression and inhibits transforming growth factor beta2-induced trabecular meshwork cell contractility. Genes. 2022;13(8):1500–1513. doi: 10.3390/genes13081500
   PubMed Web of Science ®Google Scholar
• Guo JH, Su C, Jiang SY, et al. MicroRNA-1 regulates fibronectin expression in human trabecular meshwork cells under oxidative stress. Zhonghua Yan Ke Za Zhi. 2019;55(5):355–360. doi: 10.3760/cma.j.issn.0412-4081.2019.05.009
   PubMedGoogle Scholar
• Luna C, Li G, Qiu J, et al. MicroRNA-24 regulates the processing of latent TGFβ1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. J Cell Physiol. 2011;226(5):1407–1414. doi: 10.1002/jcp.22476
   PubMed Web of Science ®Google Scholar
• Buffault J, Brignole-Baudouin F, Reboussin É, et al. The dual effect of Rho-kinase inhibition on trabecular meshwork cells cytoskeleton and extracellular matrix in an in vitro model of glaucoma. J Clin Med. 2022;11(4):1001. doi: 10.3390/jcm11041001
   PubMed Web of Science ®Google Scholar
• Peterson JA, Tian B, Bershadsky AD, et al. Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci. 1999;40(5):931–941. https://iovs.arvojournals.org/article.aspx?articleid=2162035
   PubMed Web of Science ®Google Scholar
• Peterson JA, Tian B, Geiger B, et al. Effect of latrunculin-B on outflow facility in monkeys. Exp Eye Res. 2000;70(3):307–313. doi: 10.1006/exer.1999.0797
   PubMed Web of Science ®Google Scholar
• Ha A, Kim YK, Jeoung JW, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study. Acta Ophthalmol. 2022;100(2):e470–e477. doi: 10.1111/aos.14949
   PubMed Web of Science ®Google Scholar
• Song J, Deng PF, Stinnett SS, et al. Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. Invest Ophthalmol Vis Sci. 2005;46(7):2424–2432. doi: 10.1167/iovs.04-0776
   PubMed Web of Science ®Google Scholar
• Sun Y, Li Y, Wang H, et al. miR-146a-5p acts as a negative regulator of TGF-β signaling in skeletal muscle after acute contusion. Acta Biochim Biophys Sin (Shanghai). 2017;49(7):628–634. doi: 10.1093/abbs/gmx052
   PubMed Web of Science ®Google Scholar
• Luna C, Parker M, Challa P, et al. Long-term decrease of intraocular pressure in rats by viral delivery of miR-146a. Transl Vis Sci Technol. 2021 Jul 1;10(8):14. doi: 10.1167/tvst.10.8.14
   PubMed Web of Science ®Google Scholar
• Inoue-Mochita M, Inoue T, Fujimoto T, et al. p38 MAP kinase inhibitor suppresses transforming growth factor-β2-induced type 1 collagen production in trabecular meshwork cells. PLoS One. 2015;10(3):e0120774. doi: 10.1371/journal.pone.0120774
   PubMed Web of Science ®Google Scholar
• Huang L, Wei Z, Wang X, et al. AZD6738 decreases intraocular pressure and inhibits fibrotic response in trabecular meshwork through CHK1/P53 pathway. Biochem Pharmacol. 2022;206:115340. doi: 10.1016/j.bcp.2022.115340
   PubMed Web of Science ®Google Scholar
• Mzyk P, Zalog EG, McDowell CM. A20 attenuates the fibrotic response in the trabecular meshwork. Int J Mol Sci. 2022;23(4):1928. doi: 10.3390/ijms23041928
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Inoue-Mochita M, Iraha S, et al. Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance. J Biol Chem. 2021;297(3):101070. doi: 10.1016/j.jbc.2021.101070
   PubMed Web of Science ®Google Scholar
• Shah GB, Sharma S, Mehta AA, et al. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharmacol. 2000;36(2):169–175. doi: 10.1097/00005344-200008000-00005
   PubMed Web of Science ®Google Scholar
• Constad WH, Fiore P, Samson C, et al. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1988;105(6):674–677. doi: 10.1016/0002-9394(88)90063-3
   PubMed Web of Science ®Google Scholar
• Agarwal R, Krasilnikova AV, Raja IS, et al. Mechanisms of angiotensin converting enzyme inhibitor-induced IOP reduction in normotensive rats. Eur J Pharmacol. 2014;730:8–13. doi: 10.1016/j.ejphar.2014.02.021
   PubMed Web of Science ®Google Scholar
• Agarwal R, Krasilnikova AV, Mohamed SNL, et al. Topical losartan reduces IOP by altering tm morphology in rats with steroid-induced ocular hypertension. Ind J Physiol Pharmacol. 2018;62(2):238–248.
   Google Scholar
• Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye study. Ophthalmol. 2014;121(8):1501–1507. doi: 10.1016/j.ophtha.2014.02.009
   PubMed Web of Science ®Google Scholar
• Luna C, Li G, Huang J, et al. Regulation of trabecular meshwork cell contraction and intraocular pressure by miR-200c. PLoS One. 2012;7(12):e51688. doi: 10.1371/journal.pone.0051688
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45 Suppl 4:S347–S351. doi: 10.1016/s0039-6257(01)00213-2
   PubMed Web of Science ®Google Scholar
• Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996;15(8):869–875. doi: 10.3109/02713689609017628
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Robinson MR, Dibas M, et al. Matrix Metalloproteinases and Glaucoma Treatment. J Ocul Pharmacol Ther. 2020;36(4):208–228. doi: 10.1089/jop.2019.0146
   PubMed Web of Science ®Google Scholar
• Morozumi W, Aoshima K, Inagaki S, et al. Piezo1 activation induces fibronectin reduction and PGF2α secretion via arachidonic acid cascade. Exp Eye Res. 2022;215:108917. doi: 10.1016/j.exer.2021.108917
   PubMed Web of Science ®Google Scholar
• Nakamura N, Honjo M, Yamagishi R, et al. Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm’s canal endothelial cells and ciliary muscle contraction. Sci Rep. 2021;11(1):16257. doi: 10.1038/s41598-021-95768-z
   PubMed Web of Science ®Google Scholar
• Razali N, Agarwal R, Agarwal P, et al. IOP lowering effect of topical trans-resveratrol involves adenosine receptors and TGF-β2 signaling pathways. Eur J Pharmacol. 2018;838:1–10. doi: 10.1016/j.ejphar.2018.08.035
   PubMed Web of Science ®Google Scholar
• Mohd Nasir NA, Agarwal R, Krasilnikova A, et al. Effect of trans-resveratrol on dexamethasone-induced changes in the expression of MMPs by human trabecular meshwork cells: involvement of adenosine A1 receptors and NFkB. Eur J Pharmacol. 2020;887:173431. doi: 10.1016/j.ejphar.2020.173431
   PubMed Web of Science ®Google Scholar
• Li G, Torrejon KY, Unser AM, et al. Trabodenoson, an adenosine mimetic with A1 receptor selectivity lowers intraocular pressure by increasing conventional outflow facility in mice. Invest Ophthalmol Vis Sci. 2018;59(1):383–392. doi: 10.1167/iovs.17-23212
   PubMed Web of Science ®Google Scholar
• Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther. 2007;320(1):258–265. doi: 10.1124/jpet.106.110981
   PubMed Web of Science ®Google Scholar
• Hill LJ, Mead B, Blanch RJ, et al. Decorin reduces intraocular pressure and retinal ganglion cell loss in rodents through fibrolysis of the scarred trabecular meshwork. Invest Ophthalmol Vis Sci. 2015;56(6):3743–3757. doi: 10.1167/iovs.14-15622
   PubMed Web of Science ®Google Scholar